47529300.jpg

Pharma manufacturer Dadachanji forays into building med devices

NEW DELHI: The Dadachanji Group, which is focused on pharma manufacturing and allied technologies, has forayed into building fully customised machines, medical devices, and automation solutions in pharma, healthcare, and other sectors through KAIRISH Innotech. The company will offer end-to-end capabilities across customised pharma machinery, medical device design and manufacturing, tooling and precision components, robotics…

Read More
1770508510 unnamed file.jpg

India-US trade deal: Interim pact brings ‘certainty and clarity’ for pharma sector

NEW DELHI: The interim India-US trade arrangement provides certainty and clarity to the domestic pharma sector, with medicines staying outside reciprocal tariffs, and Washington signalling negotiated treatment for generics under Section 232.India plays a critical role in supplying affordable medicines to the US, with shipments of around $10 billion accounting for nearly 35% of its…

Read More
1770488118 unnamed file.jpg

India-US trade framework expected to deepen pharma and medtech collaboration, says IPA

The interim India-US trade agreement is expected to strengthen cooperation in pharmaceuticals and medical technology, with industry bodies saying medicine supply chains are closely linked to national security priorities.Strengthening the India-US medicines partnership is important as medicine security is a part of national security, the Indian Pharmaceutical Alliance said on Saturday, welcoming the interim trade…

Read More
Pharma1.jpg

Pharma companies await clarity, eye a dose of stability in India-US deal

NEW DELHI: Drug makers are set to gain clarity under the proposed India-US trade agreement, sharpening expansion plans in the world’s most lucrative pharmaceutical market. While the sector was insulated from punitive US tariffs, the generics business of major companies, including Sun Pharma, Dr Reddy’s and Cipla faced significant headwinds in the third quarter ended…

Read More
Pollution a top priority for govt dea secretary anuradha thakur on union budget.jpg

Interview | ‘Will see more asset monetisation, inflows in chemicals, bio pharma’: Anuradha Thakur

DEA Secretary Anuradha Thakur Economic Affairs secretary Anuradha Thakur expects foreign capital inflows to improve on the back of Budget measures that have been unveiled and is confident that the growth momentum will sustain. Excerpts:Given the challenges that the economy faces, how do you see the growth-inflation dynamics playing out in the short term?■ I…

Read More
India39s futuristic healthcare hub.jpg

Budget 2026: Pharma, MedTech sectors seek structured funding push for R&D and innovation

Ahead of the Union Budget 2026, industry leaders from the pharmaceutical and MedTech sectors have called for a structured funding framework to deepen innovation and research and development (R&D), saying this is critical for realising India’s Viksit Bharat vision.Dr Reddy’s Laboratories Ltd Chairman Satish Reddy said India’s pharmaceutical industry is undergoing a strategic transition from…

Read More
1768731170 representational image.jpg

India’s pharma shipments: Brazil, Nigeria emerge as key export destinations; market expands to $20.48 billion

Even as global economic uncertainity drags down trade, Indian pharmaceutical exporters are seeing growth in Brazil and Nigeria as both countries are emerging as important overseas markets. Data by the commerce ministry data shows that Nigeria has been a major driver of this shift. During the first eight months of the current financial year, exports…

Read More
1767454840 untitled design 2.jpg

Pharma generics: Semaglutide patent expiry to open Rs 50-billion opportunity; Indian players eye FY27 boost

The impending patent expiry of semaglutide drugs across India, emerging markets and select regulated markets such as Canada and Brazil is expected to create a revenue opportunity of more than Rs 50 billion for generic pharmaceutical companies over the next 12 to 15 months, according to an industry update by Systematix Institutional Research.The report said…

Read More
1767276763 unnamed file.jpg

Aurobindo Pharma acquires branded non-oncology prescription business of Khandelwal Labs’ for Rs 325 crore

HYDERABAD: Pharma major Aurobindo Pharma is acquiring the non-oncology prescription business of Mumbai-based Khandelwal Laboratories Pvt Ltd on a going concern, slump sale basis for a cash consideration of Rs 325 crore in a move aimed at strengthening its presence in the domestic formulations market.The acquisition, done through its wholly owned subsidiary Auro Pharma Limited,…

Read More
126223442.jpg

‘Health comes first’: Finance head quits pharma firm over Delhi’s air pollution

A senior finance executive at Akums Drugs and Pharmaceuticals has resigned, citing Delhi’s severe air pollution as the primary reason. Rajkumar Bafna’s decision highlights the growing health crisis in the capital, where toxic air has become a daily struggle for residents. His departure underscores the significant personal cost of living in a city with hazardous…

Read More